The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC - Trial NCT06109558
Access comprehensive clinical trial information for NCT06109558 through Pure Global AI's free database. This phase not specified trial is sponsored by Hunan Province Tumor Hospital and is currently Not yet recruiting. The study focuses on Non Small Cell Lung Cancer. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Hunan Province Tumor Hospital
Timeline & Enrollment
N/A
Nov 01, 2023
Nov 30, 2024
Primary Outcome
ORR,PFS,DOR,DCR,OS
Summary
This is an open-label, single-arm, dose-escalation, multicenter phase I clinical trial. The
 primary endpoint of this study is to evaluated the safety, tolerability, pharmacokinetic
 profile and preliminary efficacy of HE003 in combination with osimertinib in patients with
 advanced solid tumors who have failed previous standard therapy.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06109558
Non-Device Trial